The Politics of Drug Pricing vs. Reality of Payer Control – Recorded Bloomberg Intelligence Webinar
New legislation and pilot programs are helping to change the tide when it comes to how drugs are priced in the U.S. How are these changes to payer models and legislation influencing drug pricing, and how can drug companies compete?
Dr. Bill Bithoney, Chief Physician Executive and Managing Director of BDO’s Healthcare Advisory practice, joined Bloomberg Intelligence analysts and others to address these questions and more in a recent Bloomberg webinar. Listen to the recorded version for free to hear what regulators, providers and CMS can do to impact drug pricing going forward. You’ll learn where and why indication-specific pricing is starting to take hold, why recent M&A trends are impacting biosimilar costs, and how drug companies are reacting to a more consumer-driven culture where pharmacy benefits managers have growing power.
You can watch the full webinar here